Sparsentan for the Treatment of VEGF Signaling Pathway Inhibitor-Associated Proteinuria
Sparsentan for the Treatment of VEGF Signaling Pathway Inhibitor-Associated Proteinuria
Recruiting · NCT07224776 · Registry updated 2026-07-30Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Sparsentan for the Treatment of VEGF Signaling Pathway Inhibitor-Associated Proteinuria | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Urination Disorders, Urogenital Diseases, Urological Manifestations, neoplasm, proteinuria, urinary system disorder | Recruiting | Phase 1 | 2026-07-30 | NCT07224776 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Brigham and Women's Hospital | 378 |
| Travere Therapeutics, Inc. | 10 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Brigham and Women's Hospital | Boston | United States | 511 |